Overview
Aya Haggiagi, MD is an assistant professor of neurology at CUIMC, in the Division of Neuro-Oncology. Dr. Haggiagi is board certified in Neurology and Neuro-Oncology. She graduated with highest honors from the University of Al-Fateh School of Medicine in Tripoli, Libya. She subsequently completed a postdoctoral research fellowship in the Department of Pathology and Cell Biology at Columbia, under the mentorship of Dr. Michael Shelanski, where her research focused on biochemical and genetic changes in neurofibrillary tangle predominant dementia. Dr. Haggiagi then pursued her medicine internship training at Westchester Medical Center, followed by neurology residency at NewYork-Presbyterian/Columbia University Irving Medical Center. After residency, she completed a two-year fellowship in Neuro-Oncology at Memorial Sloan Kettering Cancer Center.
Dr. Haggiagi was an attending physician and an investigator at Memorial Sloan Kettering Cancer Center prior to returning to NYP/CUIMC. She is the recipient of the Society for Neuro-Oncology 2017 Best Abstract Award. Her research interests include the development of clinical trials, precision medicine, and neurologic complications of immunotherapy.
Areas of Expertise / Conditions Treated
- Anaplastic Gliomas
- Brain Metastases
- Brain Tumor
- Cancer Immunotherapy
- Central Nervous System Tumors
- Ependymoma
- Glioblastoma
- Gliomas
- Leptomeningeal metastases
- Meningioma
- Paraneoplastic Syndromes
- Spinal Cord Tumor
Academic Appointments
- Assistant Professor of Neurology at CUMC
Hospital Affiliations
- NewYork-Presbyterian / Columbia University Irving Medical Center
Gender
- Female
Schedule an Appointment
Phone Appointments
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Location(s)
Insurance Accepted
Aetna
- Aetna Signature Administrators
- EPO
- NYP Employee Plan
- NY Signature
- PPO
- Student Health
Affinity Health Plan
- Medicaid Managed Care
Amerigroup of New Jersey
- New Jersey Services (Medicaid Managed Care)
Amida Care
- Special Needs
Cigna
- EPO
- Great West (National)
- HMO
- Medicare Managed Care
- POS
- PPO
Emblem/GHI
- Medicare Managed Care
- PPO
Emblem/HIP
- ConnectiCare
- EPO
- Essential Plan
- HMO
- Medicaid Managed Care
- Medicare Managed Care
- POS
- PPO
- Select Care (Exchange)
- Vytra
Empire Blue Cross/Blue Shield
- HMO
Empire Blue Cross Blue Shield HealthPlus
- Child/Family Health Plus
- Essential Plan
- Medicaid Managed Care
Fidelis Care
- Essential Plan
- Medicaid Managed Care
- Medicare Managed Care
Healthfirst
- Child/Family Health Plus
- Leaf (Exchange)
- Medicare Managed Care
Local 1199
- Local 1199
MagnaCare (National)
- MagnaCare
Medicare
- Railroad
- Traditional Medicare
Multiplan
- Multiplan
MVP Health Care
- Child/Family Health Plus
- Essential Plan
- Medicaid Managed Care
RiverSpring
- Special Needs
UnitedHealthcare
- Compass (Exchange)
- Empire Plan
- HMO
- Medicaid (Community Plan)
- Oxford Freedom
- Oxford HMO
- Oxford Liberty
- POS
- PPO
VNSNY CHOICE
- Medicare Managed Care
- SelectHealth
WellCare
- Medicare Managed Care
World Trade Center Health Plan
- World Trade Center Health Plan
Credentials & Experience
Education & Training
- Al-Fateh University School of Medicine
- Internship: Westchester Medical Center
- Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
- Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center
- Fellowship: Memorial Sloan-Kettering Cancer Center
Board Certifications
- Neurology
Research
Dr. Aya Haggiagi research interest is in the development of and participation in clinical trials using investigational treatments for newly diagnosed and recurrent brain tumors. She is particularly interested in clinical trials targeting specific genetic alterations identified with molecular profiling of the tumors.
Precision medicine using treatments targeting specific genetic alterations identified with molecular profiling of the tumors is a major forward step in the field of Neuro-oncology. Dr. Aya Haggiagi will be involved in several clinical trials using investigational treatments for newly diagnosed and recurrent brain tumors.